The stock of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) last traded at $6.11, down -3.32% from the previous session.
Data from the available sources indicates that Aldeyra Therapeutics Inc. (NASDAQ:ALDX) is covered by 8 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $13.00, we find $17.00. Given the previous closing price of $6.32, this indicates a potential upside of 168.99 percent. ALDX stock price is now -0.02% away from the 50-day moving average and 18.32% away from the 200-day moving average. The market capitalization of the company currently stands at $345.34M.
In total, 0 analysts have assigned it a hold rating, and 8 have given it a buy rating. Brokers who have rated the stock have averaged $19.88 as their price target over the next twelve months.
On February 08, 2021, H.C. Wainwright recently initiated its ‘Buy’ rating on the stock quoting a target price of $26, while ‘Berenberg’ rates the stock as ‘Buy’.
In other news, PERCEPTIVE ADVISORS LLC, 10% Owner bought 15,000 shares of the company’s stock on Aug 10. The stock was bought for $117,750 at an average price of $7.85. Upon completion of the transaction, the 10% Owner now directly owns 11,350,085 shares in the company, valued at $69.35 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 09, 10% Owner PERCEPTIVE ADVISORS LLC bought 100,000 shares of the business’s stock. A total of $750,000 was incurred on buying the stock at an average price of $7.50. This leaves the insider owning 11,335,085 shares of the company worth $69.26 million. A total of 2.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALDX stock. A new stake in Aldeyra Therapeutics Inc. shares was purchased by TANG CAPITAL MANAGEMENT LLC during the first quarter worth $4,277,000. J. GOLDMAN & CO LP invested $2,032,000 in shares of ALDX during the first quarter. In the first quarter, EAM INVESTORS, LLC acquired a new stake in Aldeyra Therapeutics Inc. valued at approximately $1,428,000. INVESCO LTD. acquired a new stake in ALDX for approximately $1,392,000. GSA CAPITAL PARTNERS LLP purchased a new stake in ALDX valued at around $635,000 in the second quarter. In total, there are 123 active investors with 64.90% ownership of the company’s stock.
With an opening price of $6.28 on Monday morning, Aldeyra Therapeutics Inc. (NASDAQ: ALDX) set off the trading day. During the past 12 months, Aldeyra Therapeutics Inc. has had a low of $2.36 and a high of $7.99. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 7.80, and a quick ratio of 7.80. The fifty day moving average price for ALDX is $6.11 and a two-hundred day moving average price translates $5.16 for the stock.
The latest earnings results from Aldeyra Therapeutics Inc. (NASDAQ: ALDX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.3, beating analysts’ expectations of -$0.31 by 0.01. This compares to -$0.27 EPS in the same period last year. The company reported revenue of $14.79 million for the quarter, compared to $15.44 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.25 percent.
Aldeyra Therapeutics Inc.(ALDX) Company Profile
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.